Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 273

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 273
---
 |       - |    |     | $     |  26,250 | -4 |

| (1) | This includes                                                                                                                            
 (i) option to purchase 1,125 shares of Common Stock  granted to the non-employee directors on March 25, 2024 at an exercise              
 price of $177.00 per share and (ii) option to purchase 2,550 shares of Common Stock, which vest in two equal installments subject        
 to the satisfaction of certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance criteria 
 had been met with regards to one installment, resulting in the vesting of 1,275 shares under (ii).                                       |

| (2) | This includes                                                                                                                                
 the option to purchase 2,550 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance 
 criteria; on December 2, 2024, the board of directors confirmed that the performance criteria had been met with regards to one installment,  
 resulting in the vesting of 1,275 shares. Mr. Patel received $105,000 in consulting fees pursuant to the agreement between Mr. Patel         
 and the Company.                                                                                                                             |

| (3) | This includes                                                                                                                              
 the option to purchase 1,125 shares of Common Stock granted to the non-employee director on March 25, 2024 at an exercise price of $177.00 
 per share; such award was forfeited following the directors resignation from the board of directors.                                       |

| (4) | This includes                                                                                                               
 the non-employee director compensation for the director which award was forfeited following the director’s resignation from 
 the board of directors.                                                                                                     |

<div align='center'>159

PRINCIPAL STOCKHOLDERS</div>

The
following table sets forth information regarding the beneficial ownership of our common stock
as of January 8, 2025, by:

| ● | each person known by us                                                               
 to be the beneficial owner of more than 5% of our outstanding shares of Common Stock; |

| ● | each of our named executive                                                   
 officers and directors that beneficially owns shares of our Common Stock; and |

| ● | all our executive officers 
 and directors as a group.  |

Beneficial ownership is
determined in accordance with the rules and regulations of the SEC, which generally provide that a person has beneficial ownership of
a security if he